Hookipa Pharma (HOOK) Competitors

Hookipa Pharma (NASDAQ:HOOK) and ESSA Pharma (NASDAQ:EPIX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

Which has preferable earnings and valuation, HOOK or EPIX?

ESSA Pharma has lower revenue, but higher earnings than Hookipa Pharma. ESSA Pharma is trading at a lower price-to-earnings ratio than Hookipa Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hookipa Pharma	$9.35M	1.85	-$81.58M	-$5.85	-0.24
ESSA Pharma	N/A	N/A	-$28.54M	-$0.63	-2.70

Does the media refer more to HOOK or EPIX?

In the previous week, ESSA Pharma had 1 more articles in the media than Hookipa Pharma. MarketBeat recorded 2 mentions for ESSA Pharma and 1 mentions for Hookipa Pharma. Hookipa Pharma's average media sentiment score of 1.87 beat ESSA Pharma's score of 1.73 indicating that Hookipa Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Hookipa Pharma	Very Positive
ESSA Pharma	Very Positive

Does the MarketBeat Community believe in HOOK or EPIX?

ESSA Pharma received 258 more outperform votes than Hookipa Pharma when rated by MarketBeat users. Likewise, 75.87% of users gave ESSA Pharma an outperform vote while only 69.47% of users gave Hookipa Pharma an outperform vote.

Company	Underperform	Outperform
Hookipa Pharma	Outperform Votes 91 69.47%	Underperform Votes 40 30.53%
ESSA Pharma	Outperform Votes 349 75.87%	Underperform Votes 111 24.13%

Which has more volatility & risk, HOOK or EPIX?

Hookipa Pharma has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500. Comparatively, ESSA Pharma has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500.

Do analysts rate HOOK or EPIX?

Hookipa Pharma currently has a consensus price target of $4.50, indicating a potential upside of 216.90%. ESSA Pharma has a consensus price target of $2.00, indicating a potential upside of 17.65%. Given Hookipa Pharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Hookipa Pharma is more favorable than ESSA Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hookipa Pharma	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
ESSA Pharma	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Do insiders and institutionals have more ownership in HOOK or EPIX?

63.9% of Hookipa Pharma shares are held by institutional investors. Comparatively, 75.1% of ESSA Pharma shares are held by institutional investors. 3.3% of Hookipa Pharma shares are held by company insiders. Comparatively, 15.5% of ESSA Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Is HOOK or EPIX more profitable?

ESSA Pharma has a net margin of 0.00% compared to Hookipa Pharma's net margin of -86.74%. ESSA Pharma's return on equity of -24.61% beat Hookipa Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hookipa Pharma	-86.74%	-33.31%	-21.65%
ESSA Pharma	N/A	-24.61%	-23.87%

Summary

ESSA Pharma beats Hookipa Pharma on 10 of the 17 factors compared between the two stocks.